Novo Nordisk gift creates University of Toronto/Banting and Best Diabetes Centre student environment.TORONTO--(BUSINESS WIRE)--Oct. 8, 1996--Novo Nordisk A/S (NYSE NYSE See: New York Stock Exchange :NVO NVO no visible oestrus (see no visible estrus). Called also NVE. ) has commemorated the 75th Anniversary of the discovery of insulin and honored the institution that enabled Novo Nordisk Wikipedia is not the place for advertisement or self-advertising. Novo Nordisk (, NYSE: NVO) manufactures and markets pharmaceutical products and services. Founded in Denmark in 1923, the company has since become a world leader in diabetes care with the broadest to become the world leader in the production of insulin through a gift that will live long into the future. The University of Toronto/Banting and Best Diabetes Centre/Novo Nordisk Award has been announced. The Novo Nordisk gift of $1.4 million (CDN (Content Delivery Network) A system of distributed content on a large intranet or the public Internet in which copies of content are replicated and cached throughout the network. ) will be matched by the University of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, (U of T) and again by the Province of Ontario under the terms of the Ontario Student Opportunity Trust Fund to create a $4.2 million endowment. The endowment will benefit the U of T's award program for students in the Faculty of Medicine in connection with research at the Banting and Best Diabetes Centre. The University of Toronto has also committed, in collaboration with Novo Nordisk, to establishing research fellowships each year for three years beginning in 1997. This research fellowship program is designed to facilitate the exchange of ideas between Banting and Best Diabetes Centre and the Novo Nordisk world-class research facilities, ZymoGenetics in Seattle and Hagedorn Research Institute in Denmark. In addition, an annual symposium will be organized jointly by the Banting and Best Diabetes Centre and Novo Nordisk. The symposium will enable research activities to be presented on a regular basis. Mads Ovilsen, president and chief executive officer of Novo Nordisk announced the gift at the Novo Nordisk celebratory dinner last night at the Royal Ontario museum The Royal Ontario Museum, commonly known as the ROM (rhyming with Tom), is a major museum for world culture and natural history in the city of Toronto, Ontario, Canada. . He said, "This is a very special occasion. Novo Nordisk takes this opportunity to say `thank you' to Canada for generously sharing the discovery of insulin. Insulin and Novo Nordisk are joined by history, and we are proud to give back to the Banting and Best Diabetes Centre some of what we were given -- science on the road to better treatments and a cure." Ovilsen added, "We see investing in students as an investment in the future of research. After all, Dr. Charles Best Dr. Charles Herbert Best, CC (February 27, 1899 – March 31, 1978) was a medical scientist. He was born in West Pembroke, Maine, USA to Canadian parents. While a 22-year-old student studying medicine at the University of Toronto, he worked as an assistant to Dr. , one of the discoverers was a medical student who was given a small amount of money to conduct research with Sir Frederick Banting Sir Frederick Grant Banting, KBE, MC, MD, FRSC (November 14, 1891 – February 21, 1941) was a Canadian medical scientist, doctor and Nobel laureate noted as one of the co-discovers of insulin. Banting was born in Alliston, Ontario, Canada. and insulin was the result." Dr. Bernard Zinman, director of the Banting and Best Diabetes Centre said, "We are enthusiastic about this generous gift, the opportunity to collaborate with Novo Nordisk, and the student aid which will result. I believe our relationship helps us reach a mutual goal of fostering excellence in medical education and attracting the best creative minds to the field of medical research." Dr. Daniel Drucker, director of the U of T's Division of Endocrinology added, "This endowment is a wonderful tribute to Canada. It honors the contribution made by Banting and Best and Canada's desire to share that important discovery with the world. It also marks the beginning of an ongoing collaborative relationship with Novo Nordisk to further research on an global scale." Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore, the company is the world's largest producer of industrial enzymes. Headquartered in Denmark, Novo Nordisk employs approximately 13,400 people in 54 countries and markets its products in 130 countries. Its B shares are listed on the stock exchanges in Copenhagen, London and Zurich. Its ADSs are listed on the New York Stock Exchange New York Stock Exchange (NYSE) World's largest marketplace for securities. The exchange began as an informal meeting of 24 men in 1792 on what is now Wall Street in New York City. under the symbol "NVO". CONTACT: Novo Nordisk of North America, Inc. Susan Jackson, Corporate Communications 212/867-0123 or Fax: 212/986-6499 Peter Baekgaard, Investor Relations Investor relations The process by which the corporation communicates with its investors. 212/867-0123 or Fax: 212/867-0298 or University of Toronto Kim Luke, 416/978-2105 or Fax: 416/978-1632 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion